This study aims to assess the proportion of participants with moderate-to-severe plaque psoriasis who continue treatment with guselkumab over a two-year period.
Has a confirmed diagnosis of moderate-to-severe plaque psoriasis
Participant must sign an informed consent form allowing source data verification in accordance with local requirements
Is able to read, understand, and complete the patient reported outcomes (PRO) instruments in local language and comply with completion of all PRO instruments
No previous exposure to biological treatment, including guselkumab (bio-naive patient)
Meets any of the contraindications according to the latest version of the locally approved summary of product characteristics (SmPC)
Is pregnant or lactating
Current or recent (in the last 30 days prior to first SC dose of guselkumab) participation in any interventional study with investigational product.
Currently enrolled in another observational study sponsored or managed by a Johnson & Johnson company